Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators
Objective For risk stratification of sudden cardiac death in patients with structural heart disease, more precise predictors in addition to left ventricular ejection fraction (LVEF) are clinically needed. The present study assessed the utility of galectin-3 as an independent indicator for the progno...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2022/04/01, Vol.61(7), pp.969-977 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 977 |
|---|---|
| container_issue | 7 |
| container_start_page | 969 |
| container_title | Internal Medicine |
| container_volume | 61 |
| creator | Makimoto, Hisaki Müller, Patrick Denise, Kullmann Clasen, Lukas Lin, Tina Angendohr, Stephan Schmidt, Jan Brinkmeyer, Christoph Kelm, Malte Bejinariu, Alexandru |
| description | Objective For risk stratification of sudden cardiac death in patients with structural heart disease, more precise predictors in addition to left ventricular ejection fraction (LVEF) are clinically needed. The present study assessed the utility of galectin-3 as an independent indicator for the prognosis of heart failure patients with implantable cardioverter-defibrillators (ICD). Methods The study population consisted of 91 consecutive patients who underwent a routine ICD checkup in our ICD outpatient clinic. Circulating galectin-3 was assessed using a commercially available enzyme-linked immunosorbent assay kit. The enrolled patients were prospectively followed. The primary endpoint was defined as the occurrence of appropriate ICD therapy (AIT), and the secondary endpoint was defined as the occurrence of unplanned overnight hospitalization due to decompensated heart failure (dHF). Results During a mean follow-up of 472±107 days, AIT occurred in 18 patients (20%). Unplanned hospitalizations due to dHF were noted in 12 patients (13%). A receiver-operative characteristics analysis demonstrated a sensitivity of 83% and specificity of 68% for AIT occurrences with a galectin-3 cut-off value of 13.1 ng/mL (area under the curve =0.82). A Kaplan-Meier analysis demonstrated that patients with galectin-3 >13.1 ng/mL had significantly higher incidences of AIT as compared to those with lower galectin-3 (log-rank, p |
| doi_str_mv | 10.2169/internalmedicine.7886-21 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9038450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646155409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-98765fdf5ced1d9c274f9b103e575cb92e53fb986163324102986e0c9182cea53</originalsourceid><addsrcrecordid>eNptUk1vEzEQXSEQDYW_gCxx4bLFH-vd9QWpitomUgU9AFfL651NHDl2sL2pys_kF-FNSgSFy3jkefPm6xUFIviCklp8MC5BcMpuoTfaOLho2rYuKXlWzAirRNlQxp8XMyxIW9JszopXMW4wZm0j6MvijHHWYMqrWfFzbo0zWlm03O6UTsgPaG6CHq1Kxq3QjbKgs1cy5B36Bi4FMwUDugxh_ZDWW6MiUq5HC1AhoWtl7BgALXzcmaSs-ZF5cubS9bCDbNyhxF0wPvyfTqOrff6PyDh0l5MP_r1J66lDq1xSnQU0V6E3fg8hL6LsYTBdMDb37EN8XbwYlI3w5vE9L75eX32ZL8rbzzfL-eVtqWssUinapuZDP3ANPemFpk01iI5gBrzhuhMUOBs60dakZoxWBNPsA9Z5nVSD4uy8-Hjk3Y1dPoSehlFW7oLZqvAgvTLy74gza7nyeynyHSqOM8H7R4Lgv48Qk9yaqCGP4cCPUdK6qkVFsagz9N0T6MaPkwKOKMJ5hUVGtUeUDj7GAMOpGYLlJBz5VDhyEk4O5dS3fw5zSvytlAz4dARsYlIrOAHy0Y228C9zTWRzMMcKJ6BeqyDBsV8PBOgu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646155409</pqid></control><display><type>article</type><title>Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Makimoto, Hisaki ; Müller, Patrick ; Denise, Kullmann ; Clasen, Lukas ; Lin, Tina ; Angendohr, Stephan ; Schmidt, Jan ; Brinkmeyer, Christoph ; Kelm, Malte ; Bejinariu, Alexandru</creator><creatorcontrib>Makimoto, Hisaki ; Müller, Patrick ; Denise, Kullmann ; Clasen, Lukas ; Lin, Tina ; Angendohr, Stephan ; Schmidt, Jan ; Brinkmeyer, Christoph ; Kelm, Malte ; Bejinariu, Alexandru</creatorcontrib><description>Objective For risk stratification of sudden cardiac death in patients with structural heart disease, more precise predictors in addition to left ventricular ejection fraction (LVEF) are clinically needed. The present study assessed the utility of galectin-3 as an independent indicator for the prognosis of heart failure patients with implantable cardioverter-defibrillators (ICD). Methods The study population consisted of 91 consecutive patients who underwent a routine ICD checkup in our ICD outpatient clinic. Circulating galectin-3 was assessed using a commercially available enzyme-linked immunosorbent assay kit. The enrolled patients were prospectively followed. The primary endpoint was defined as the occurrence of appropriate ICD therapy (AIT), and the secondary endpoint was defined as the occurrence of unplanned overnight hospitalization due to decompensated heart failure (dHF). Results During a mean follow-up of 472±107 days, AIT occurred in 18 patients (20%). Unplanned hospitalizations due to dHF were noted in 12 patients (13%). A receiver-operative characteristics analysis demonstrated a sensitivity of 83% and specificity of 68% for AIT occurrences with a galectin-3 cut-off value of 13.1 ng/mL (area under the curve =0.82). A Kaplan-Meier analysis demonstrated that patients with galectin-3 >13.1 ng/mL had significantly higher incidences of AIT as compared to those with lower galectin-3 (log-rank, p<0.001). This significance was also observed in both subgroup analyses with ischemic and non-ischemic etiology. Cox regression demonstrated that higher galectin-3 was an independent predictor of AIT and dHF, even after adjusting for previous arrhythmic events. Conclusion The circulating galectin-3 level can be used as a clinical indicator of subsequent occurrence of ventricular arrhythmic events and decompensated heart failure, regardless of a history of ventricular arrhythmias.</description><identifier>ISSN: 0918-2918</identifier><identifier>ISSN: 1349-7235</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.7886-21</identifier><identifier>PMID: 35370254</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Arrhythmia ; Arrhythmias, Cardiac - etiology ; Cardiac arrhythmia ; Congestive heart failure ; Coronary artery disease ; Defibrillators ; Defibrillators, Implantable - adverse effects ; Enzyme-linked immunosorbent assay ; Etiology ; Galectin 3 ; Heart failure ; Heart Failure - complications ; Heart Failure - therapy ; Hospitalization ; Humans ; implantable cardioverter-defibrillator ; Internal medicine ; Ischemia ; ischemic cardiomyopathy ; non-ischemic cardiomyopathy ; Original ; Patients ; Population studies ; Stroke Volume ; Ventricle ; Ventricular Function, Left ; ventricular tachycardia</subject><ispartof>Internal Medicine, 2022/04/01, Vol.61(7), pp.969-977</ispartof><rights>2022 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><rights>Copyright © 2022 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-98765fdf5ced1d9c274f9b103e575cb92e53fb986163324102986e0c9182cea53</citedby><cites>FETCH-LOGICAL-c609t-98765fdf5ced1d9c274f9b103e575cb92e53fb986163324102986e0c9182cea53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038450/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038450/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,1877,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35370254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Makimoto, Hisaki</creatorcontrib><creatorcontrib>Müller, Patrick</creatorcontrib><creatorcontrib>Denise, Kullmann</creatorcontrib><creatorcontrib>Clasen, Lukas</creatorcontrib><creatorcontrib>Lin, Tina</creatorcontrib><creatorcontrib>Angendohr, Stephan</creatorcontrib><creatorcontrib>Schmidt, Jan</creatorcontrib><creatorcontrib>Brinkmeyer, Christoph</creatorcontrib><creatorcontrib>Kelm, Malte</creatorcontrib><creatorcontrib>Bejinariu, Alexandru</creatorcontrib><title>Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Objective For risk stratification of sudden cardiac death in patients with structural heart disease, more precise predictors in addition to left ventricular ejection fraction (LVEF) are clinically needed. The present study assessed the utility of galectin-3 as an independent indicator for the prognosis of heart failure patients with implantable cardioverter-defibrillators (ICD). Methods The study population consisted of 91 consecutive patients who underwent a routine ICD checkup in our ICD outpatient clinic. Circulating galectin-3 was assessed using a commercially available enzyme-linked immunosorbent assay kit. The enrolled patients were prospectively followed. The primary endpoint was defined as the occurrence of appropriate ICD therapy (AIT), and the secondary endpoint was defined as the occurrence of unplanned overnight hospitalization due to decompensated heart failure (dHF). Results During a mean follow-up of 472±107 days, AIT occurred in 18 patients (20%). Unplanned hospitalizations due to dHF were noted in 12 patients (13%). A receiver-operative characteristics analysis demonstrated a sensitivity of 83% and specificity of 68% for AIT occurrences with a galectin-3 cut-off value of 13.1 ng/mL (area under the curve =0.82). A Kaplan-Meier analysis demonstrated that patients with galectin-3 >13.1 ng/mL had significantly higher incidences of AIT as compared to those with lower galectin-3 (log-rank, p<0.001). This significance was also observed in both subgroup analyses with ischemic and non-ischemic etiology. Cox regression demonstrated that higher galectin-3 was an independent predictor of AIT and dHF, even after adjusting for previous arrhythmic events. Conclusion The circulating galectin-3 level can be used as a clinical indicator of subsequent occurrence of ventricular arrhythmic events and decompensated heart failure, regardless of a history of ventricular arrhythmias.</description><subject>Arrhythmia</subject><subject>Arrhythmias, Cardiac - etiology</subject><subject>Cardiac arrhythmia</subject><subject>Congestive heart failure</subject><subject>Coronary artery disease</subject><subject>Defibrillators</subject><subject>Defibrillators, Implantable - adverse effects</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Etiology</subject><subject>Galectin 3</subject><subject>Heart failure</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>implantable cardioverter-defibrillator</subject><subject>Internal medicine</subject><subject>Ischemia</subject><subject>ischemic cardiomyopathy</subject><subject>non-ischemic cardiomyopathy</subject><subject>Original</subject><subject>Patients</subject><subject>Population studies</subject><subject>Stroke Volume</subject><subject>Ventricle</subject><subject>Ventricular Function, Left</subject><subject>ventricular tachycardia</subject><issn>0918-2918</issn><issn>1349-7235</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUk1vEzEQXSEQDYW_gCxx4bLFH-vd9QWpitomUgU9AFfL651NHDl2sL2pys_kF-FNSgSFy3jkefPm6xUFIviCklp8MC5BcMpuoTfaOLho2rYuKXlWzAirRNlQxp8XMyxIW9JszopXMW4wZm0j6MvijHHWYMqrWfFzbo0zWlm03O6UTsgPaG6CHq1Kxq3QjbKgs1cy5B36Bi4FMwUDugxh_ZDWW6MiUq5HC1AhoWtl7BgALXzcmaSs-ZF5cubS9bCDbNyhxF0wPvyfTqOrff6PyDh0l5MP_r1J66lDq1xSnQU0V6E3fg8hL6LsYTBdMDb37EN8XbwYlI3w5vE9L75eX32ZL8rbzzfL-eVtqWssUinapuZDP3ANPemFpk01iI5gBrzhuhMUOBs60dakZoxWBNPsA9Z5nVSD4uy8-Hjk3Y1dPoSehlFW7oLZqvAgvTLy74gza7nyeynyHSqOM8H7R4Lgv48Qk9yaqCGP4cCPUdK6qkVFsagz9N0T6MaPkwKOKMJ5hUVGtUeUDj7GAMOpGYLlJBz5VDhyEk4O5dS3fw5zSvytlAz4dARsYlIrOAHy0Y228C9zTWRzMMcKJ6BeqyDBsV8PBOgu</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Makimoto, Hisaki</creator><creator>Müller, Patrick</creator><creator>Denise, Kullmann</creator><creator>Clasen, Lukas</creator><creator>Lin, Tina</creator><creator>Angendohr, Stephan</creator><creator>Schmidt, Jan</creator><creator>Brinkmeyer, Christoph</creator><creator>Kelm, Malte</creator><creator>Bejinariu, Alexandru</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220401</creationdate><title>Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators</title><author>Makimoto, Hisaki ; Müller, Patrick ; Denise, Kullmann ; Clasen, Lukas ; Lin, Tina ; Angendohr, Stephan ; Schmidt, Jan ; Brinkmeyer, Christoph ; Kelm, Malte ; Bejinariu, Alexandru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-98765fdf5ced1d9c274f9b103e575cb92e53fb986163324102986e0c9182cea53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Arrhythmia</topic><topic>Arrhythmias, Cardiac - etiology</topic><topic>Cardiac arrhythmia</topic><topic>Congestive heart failure</topic><topic>Coronary artery disease</topic><topic>Defibrillators</topic><topic>Defibrillators, Implantable - adverse effects</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Etiology</topic><topic>Galectin 3</topic><topic>Heart failure</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>implantable cardioverter-defibrillator</topic><topic>Internal medicine</topic><topic>Ischemia</topic><topic>ischemic cardiomyopathy</topic><topic>non-ischemic cardiomyopathy</topic><topic>Original</topic><topic>Patients</topic><topic>Population studies</topic><topic>Stroke Volume</topic><topic>Ventricle</topic><topic>Ventricular Function, Left</topic><topic>ventricular tachycardia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Makimoto, Hisaki</creatorcontrib><creatorcontrib>Müller, Patrick</creatorcontrib><creatorcontrib>Denise, Kullmann</creatorcontrib><creatorcontrib>Clasen, Lukas</creatorcontrib><creatorcontrib>Lin, Tina</creatorcontrib><creatorcontrib>Angendohr, Stephan</creatorcontrib><creatorcontrib>Schmidt, Jan</creatorcontrib><creatorcontrib>Brinkmeyer, Christoph</creatorcontrib><creatorcontrib>Kelm, Malte</creatorcontrib><creatorcontrib>Bejinariu, Alexandru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Makimoto, Hisaki</au><au>Müller, Patrick</au><au>Denise, Kullmann</au><au>Clasen, Lukas</au><au>Lin, Tina</au><au>Angendohr, Stephan</au><au>Schmidt, Jan</au><au>Brinkmeyer, Christoph</au><au>Kelm, Malte</au><au>Bejinariu, Alexandru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>61</volume><issue>7</issue><spage>969</spage><epage>977</epage><pages>969-977</pages><artnum>7886-21</artnum><issn>0918-2918</issn><issn>1349-7235</issn><eissn>1349-7235</eissn><abstract>Objective For risk stratification of sudden cardiac death in patients with structural heart disease, more precise predictors in addition to left ventricular ejection fraction (LVEF) are clinically needed. The present study assessed the utility of galectin-3 as an independent indicator for the prognosis of heart failure patients with implantable cardioverter-defibrillators (ICD). Methods The study population consisted of 91 consecutive patients who underwent a routine ICD checkup in our ICD outpatient clinic. Circulating galectin-3 was assessed using a commercially available enzyme-linked immunosorbent assay kit. The enrolled patients were prospectively followed. The primary endpoint was defined as the occurrence of appropriate ICD therapy (AIT), and the secondary endpoint was defined as the occurrence of unplanned overnight hospitalization due to decompensated heart failure (dHF). Results During a mean follow-up of 472±107 days, AIT occurred in 18 patients (20%). Unplanned hospitalizations due to dHF were noted in 12 patients (13%). A receiver-operative characteristics analysis demonstrated a sensitivity of 83% and specificity of 68% for AIT occurrences with a galectin-3 cut-off value of 13.1 ng/mL (area under the curve =0.82). A Kaplan-Meier analysis demonstrated that patients with galectin-3 >13.1 ng/mL had significantly higher incidences of AIT as compared to those with lower galectin-3 (log-rank, p<0.001). This significance was also observed in both subgroup analyses with ischemic and non-ischemic etiology. Cox regression demonstrated that higher galectin-3 was an independent predictor of AIT and dHF, even after adjusting for previous arrhythmic events. Conclusion The circulating galectin-3 level can be used as a clinical indicator of subsequent occurrence of ventricular arrhythmic events and decompensated heart failure, regardless of a history of ventricular arrhythmias.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>35370254</pmid><doi>10.2169/internalmedicine.7886-21</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2022/04/01, Vol.61(7), pp.969-977 |
| issn | 0918-2918 1349-7235 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9038450 |
| source | J-STAGE Free; MEDLINE; PubMed Central Open Access; PubMed Central |
| subjects | Arrhythmia Arrhythmias, Cardiac - etiology Cardiac arrhythmia Congestive heart failure Coronary artery disease Defibrillators Defibrillators, Implantable - adverse effects Enzyme-linked immunosorbent assay Etiology Galectin 3 Heart failure Heart Failure - complications Heart Failure - therapy Hospitalization Humans implantable cardioverter-defibrillator Internal medicine Ischemia ischemic cardiomyopathy non-ischemic cardiomyopathy Original Patients Population studies Stroke Volume Ventricle Ventricular Function, Left ventricular tachycardia |
| title | Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T05%3A22%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Impact%20of%20Circulating%20Galectin-3%20on%20Ventricular%20Arrhythmias%20and%20Heart%20Failure%20Hospitalization%20Independent%20of%20Prior%20Ventricular%20Arrhythmic%20Events%20in%20Patients%20with%20Implantable%20Cardioverter-defibrillators&rft.jtitle=Internal%20Medicine&rft.au=Makimoto,%20Hisaki&rft.date=2022-04-01&rft.volume=61&rft.issue=7&rft.spage=969&rft.epage=977&rft.pages=969-977&rft.artnum=7886-21&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.7886-21&rft_dat=%3Cproquest_pubme%3E2646155409%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2646155409&rft_id=info:pmid/35370254&rfr_iscdi=true |